These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20850576)

  • 1. The societal burden of poor persistence to treatment of osteoporosis in Sweden.
    Landfeldt E; Lundkvist J; Ström O
    Bone; 2011 Feb; 48(2):380-8. PubMed ID: 20850576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost effective osteoporosis therapy. Alendronate is also immediately available as a generic drug].
    MMW Fortschr Med; 2005 Dec; 147(49-50):74-5. PubMed ID: 16401016
    [No Abstract]   [Full Text] [Related]  

  • 3. Potential clinical and economic impact of nonadherence with osteoporosis medications.
    Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
    Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of therapy with teriparatide and alendronate in women with severe osteoporosis.
    Liu H; Michaud K; Nayak S; Karpf DB; Owens DK; Garber AM
    Arch Intern Med; 2006 Jun; 166(11):1209-17. PubMed ID: 16772249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.
    Borgström F; Johnell O; Jönsson B; Zethraeus N; Sen SS
    Bone; 2004 Jun; 34(6):1064-71. PubMed ID: 15193554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The societal burden of osteoporosis in Sweden.
    Borgström F; Sobocki P; Ström O; Jönsson B
    Bone; 2007 Jun; 40(6):1602-9. PubMed ID: 17433804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of integrating medication adherence into pharmacoeconomic analyses: the example of osteoporosis.
    Hiligsmann M; Boonen A; Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2012 Apr; 12(2):159-66. PubMed ID: 22458617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of alendronate on bone mineral density in Puerto Rican males with osteoporosis.
    Martinó A; Rosa J; Guzmán J; Ramírez M
    P R Health Sci J; 2005 Jun; 24(2):131-5. PubMed ID: 16116930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
    Boonen S
    Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem.
    Cramer JA; Silverman S
    Am J Med; 2006 Apr; 119(4 Suppl 1):S12-7. PubMed ID: 16563936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the current anti-osteoporotic therapy paradigm good enough?
    Fisher AA; Davis MW
    J Am Geriatr Soc; 2006 Dec; 54(12):1960-1, author reply 1961-3. PubMed ID: 17198519
    [No Abstract]   [Full Text] [Related]  

  • 12. [Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy].
    Palomo Atance E; Ballester Herrera MJ; Márquez de La Plata MA; Medina Cano E; Carmona Vilchez RM
    An Pediatr (Barc); 2011 Feb; 74(2):122-5. PubMed ID: 21169073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Osteoporosis: from cost-effect characteristics to clinical efficacy and safety of strontium ranelate (bivalos)].
    Dydykina IS; Tsurko VV
    Ter Arkh; 2008; 80(5):85-91. PubMed ID: 18590124
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone densitometry and treatment for osteoporosis in older men.
    Ito K
    JAMA; 2007 Nov; 298(18):2136-7; author reply 2137. PubMed ID: 18000194
    [No Abstract]   [Full Text] [Related]  

  • 15. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of alendronate on glucocorticoid-induced osteoporosis].
    Zou X; Li Q; Shi C
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2009 Jun; 34(6):563-5. PubMed ID: 19587443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Rossi CM; Di Comite G
    N Engl J Med; 2008 Mar; 358(12):1302; author reply 1303-4. PubMed ID: 18354112
    [No Abstract]   [Full Text] [Related]  

  • 18. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women.
    Schousboe JT; Ensrud KE; Nyman JA; Melton LJ; Kane RL
    J Am Geriatr Soc; 2005 Oct; 53(10):1697-704. PubMed ID: 16181168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Compliance with treatment in osteoporosis patients--an ongoing problem.
    Sambrook P
    Aust Fam Physician; 2006 Mar; 35(3):135-7. PubMed ID: 16525527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming problems with adherence to osteoporosis medication.
    Rabenda V; Reginster JY
    Expert Rev Pharmacoecon Outcomes Res; 2010 Dec; 10(6):677-89. PubMed ID: 21155701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.